{"id":40315,"date":"2023-09-20T15:35:28","date_gmt":"2023-09-20T15:35:28","guid":{"rendered":"https:\/?p=40315"},"modified":"2023-09-20T15:35:28","modified_gmt":"2023-09-20T15:35:28","slug":"amam-stock-soars-7-following-significant-insider-investment","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/amam-stock-soars-7-following-significant-insider-investment\/","title":{"rendered":"AMAM Stock Soars 7% Following Significant Insider Investment"},"content":{"rendered":"

Ambrx Biopharma (AMAM:NSD<\/a>) is a clinical-stage biopharmaceutical company renowned for its pioneering work in Engineered Precision Biologics through expanded genetic code technology. AMAM stock witnessed a significant boost in its stock price in Wednesday\u2019s pre-market trade. The surge comes in the wake of a substantial insider purchase by Cormorant Asset Management.<\/p>\n

 <\/p>\n

Significant AMAM Stock Acquisition:<\/h2>\n

Cormorant Asset Management, a major stakeholder in Ambrx Biopharma with ownership exceeding 10%, executed a substantial acquisition of 2.15 million AMAM shares on September 15 and September 18.<\/p>\n

Cormorant Asset Management made this acquisition at an attractive weighted average price of $9.11 per share, resulting in a total transaction value of $19.61 million. Following this purchase, Cormorant’s holdings in AMAM stock have now surged to an estimated $712 million.<\/p>\n

 <\/p>\n

Cormorant’s Investment Track Record:<\/h2>\n

The investment prowess of Cormorant Asset Management is not to be underestimated. Over the past three months, the firm has achieved an impressive success rate of 71% in its investment decisions. Furthermore, their investments have yielded an average return of 17.4% per transaction. This track record underscores the significance of Cormorant’s recent move in the AMAM stock.<\/p>\n

 <\/p>\n

AMAM Stock’s Future Outlook:<\/h2>\n

Furthermore, Ambrx Biopharma’s groundbreaking approach to cancer therapeutics, complemented by promising preliminary results and strategic collaborations, positions the company for substantial growth in the foreseeable future.<\/p>\n

 <\/p>\n

AMAM Stock Forecast:<\/h2>\n

The average target price for Amam is $22.57 over the next 12 months. It’s worth noting that the average analyst rating for the company stands at “Strong Buy.”<\/p>\n

Stock Target Advisor’s analyst’s assessment categorizes Ambrx Biopharma Inc. American Depositary Shares as “Slightly Bullish.” This analysis is based on nine key signals, including six positive and three negative.<\/p>\n

<\/p>\n

\n
\n

AMAM Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n